Condition: Neoplasms · Prostatic Neoplasms, Castration-Resistant · Stomach Neoplasms · Sponsor: Cancer Research UK
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
This description comes directly from the study's public registry record.
Bristi Basu, Dr · +44 (0) 1223 769310 · Bristi.Basu@nhs.net
Always discuss trial participation with your own doctor first.
| Addenbrooke's Hospital | Cambridge, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, United Kingdom | Recruiting |
| Clatterbridge Cancer Centre | Liverpool, United Kingdom | Recruiting |
| Guy's Hospital | London, United Kingdom | Recruiting |
| The Christie Hospital | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05944237